Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 2 months ago
Share
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
375 patients around the world
Available in
Spain, United States, Brazil
ArriVent BioPharma, Inc.
375
Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Inclusion criteria
Exclusion criteria
See details
Contact us
Contact us
Sponsor
ArriVent BioPharma, Inc.
Conditions
Non-small cell lung carcinoma
Requirements
From 18 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT05607550
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent